{"public_id":"cl_6b59e7f168c4bf01522da3963122df4e","status":"active","superseded_by_public_id":null,"corpus_id":26614083,"text":"Pharmaceutical examples are presented in which the presence of the amorphous state is important.","confidence":0.9,"paper":{"corpus_id":26614083,"title":"Characteristics and significance of the amorphous state in pharmaceutical systems.","url":"https://sah.borca.ai/papers/26614083"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.9,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_339e326f812bf1f07d8aeacddebf9450","name":"amorphous state","description":"A non-crystalline solid-state form of a pharmaceutical material.","types":["material state"],"url":"https://sah.borca.ai/concepts/co_339e326f812bf1f07d8aeacddebf9450"},{"public_id":"co_fe88bca27861b50554c55b3c887e68a4","name":"pharmaceutical situations","description":"Pharmaceutical contexts or cases where amorphous material is relevant.","types":["context"],"url":"https://sah.borca.ai/concepts/co_fe88bca27861b50554c55b3c887e68a4"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_6b59e7f168c4bf01522da3963122df4e"}